Veit De Maddalena: «After the Transformation, We Are Now in a Transition Year»
Bellevue Group completed a major restructuring and sold private equity arm Adbodmer, cutting personnel and costs while maintaining an 88% healthcare allocation; CEO Veit De Maddalena expects 2026 to be a transition year with a 10% AUM growth target and improved cost-income and ROE goals despite a CHF550 million currency headwind from dollar depreciation.
Why it mattersWith 88% healthcare allocation and CHF550 million currency hit, portfolio managers must increase dollar hedging.
Entities Mentioned
Bellevue GroupBellevue AM GermanyAdbodmerPfizerBB BiotechUS government
People Mentioned
Veit De Maddalena